Appendix A. Symptom ratings in pilot study.

Rating no.	Before	0.02 ppm	0.04 ppm	0.07 ppm	0.1 ppm	0.2 ppm	0.3 ppm
1. Discomfort in the eyes	0.0 (0–13)	1.5 (0–10)	0.0 (0–33)	0.0 (0–36)	0.0 (0–26)	0.0 (0–13)	0.0 (0–61)
2. Discomfort in the nose	3.0 (0–31)	2.0 (0–28)	2.0 (0–38)	2.0 (0–49)	0.0 (0–45)	0.0 (0–48)	0.0 (0–51)
3. Discomfort in the throat	0.0 (0–27)	1.5 (0–47)	3.0 (0–60)	3.0 (0–48)	3.0 (0–38)	5.5 (0–29)	6.0 (0–59)
4. Breathing difficulty	0.0 (0–5)	0.0 (0–13)	0.0 (0–7)	1.5 (0–16)	1.0 (0–38)	0.0 (0–26)	0.0 (0–21)
5. Solvent smell	0.0 (0–6)	13.0 (0–51)	6.0 (0–29)	6.0 (0–16)	4.0 (0–38)	6.0 (0–39)	4.0 (0–48)
6. Headache	0.0 (0–24)	0.0 (0–24)	0.0 (0–16)	0.0 (0–19)	0.0 (0–25)	0.0 (0–15)	0.0 (0–16)
7. Fatigue	2.0 (0–30)	0.0 (0–12)	3.0 (0–17)	1.0 (0–27)	8.0 (0–26)	7.5 (0–32)	11.5 (0–39)
8. Nausea	0.0 (0–7)	0.0 (0–15)	0.0 (0–18)	0.0 (0–11)	0.0 (0–9)	0.0 (0–11)	0.0 (0–7)
9. Dizziness	0.0 (0–3)	0.0 (0–2)	0.0 (0–3)	0.0 (0–11)	0.0 (0–12)	0.0 (0–6)	0.0 (0–9)
10.Feeling of intoxication	0.0 (0–3)	0.0 (0–6)	0.0 (0–3)	0.0 (0–9)	0.0 (0–12)	0.0 (0–8)	0.0 (0–9)

Results of symptom ratings of eight volunteers measured before and every 10 min after stepwise increasing the concentration from 0.02 to 0.3 ppm of acrolein in the pilot study. Values are given as median with range in parentheses.